Almoosawy Sayed Abdulmotaleb, Esmaiel Abdullah, Farrag Ibrahim, Al Jarallah Mohammad, Zubaid Mohammad
Department of Internal Medicine, Al-Amiri Hospital, Ministry of Health, Kuwait City, Kuwait.
Department of Medicine, Division of Cardiology, Mubarak Al-Kabeer Hospital, Ministry of Health, Kuwait City, Kuwait.
Heart Views. 2024 Apr-Jun;25(2):57-62. doi: 10.4103/heartviews.heartviews_50_24. Epub 2024 Oct 10.
Emerging evidence from various countries suggests that ST-segment elevation myocardial infarction (STEMI) patients with differing health-care insurance types experience discrepancies in clinical management and outcomes. Kuwait government provides free essential treatments and medications to noninsured patients with certain emergency conditions. We aimed to compare differences in clinical management and in-hospital and 30-day outcomes in STEMI patients with different insurance types in Kuwait.
Data were derived from Kuwait Catheterization Laboratory Project (Kuwait CLAP) registry. Adult patients (≥18 years) diagnosed with STEMI were enrolled in Kuwait CLAP registry between February 2020 and February 2021. Patients were categorized into insured and noninsured. The coprimary outcomes were the in-hospital and 30-day mortality in insured versus noninsured patients with STEMI. In-hospital and 30-day adverse cardiac outcomes were also compared.
Of 668 patients with STEMI, 116 (17%) were insured and 552 (83%) were not insured. Three (2.6%) of the insured and 9 (1.6%) of the noninsured patients suffered in-hospital mortality, while no patients in the insured group and four patients (0.7%) patients in the noninsured group suffered 30-day mortality, with no significant difference between the two groups ( = 0.447 and = 1, respectively). The rates of in-hospital complications and 30-day adverse events were similar between the two groups.
Our findings suggest no differences in acute or short-term outcomes among patients with different insurance status in Kuwait. These findings are reassuring knowing that the free essential services provided by Kuwait government for STEMI patients did not compromise the outcomes of noninsured compared to insured patients.
来自各国的新证据表明,患有不同医疗保险类型的ST段抬高型心肌梗死(STEMI)患者在临床管理和治疗结果方面存在差异。科威特政府为患有某些紧急病症的未参保患者提供免费的基本治疗和药物。我们旨在比较科威特不同保险类型的STEMI患者在临床管理、住院期间及30天治疗结果方面的差异。
数据来源于科威特导管实验室项目(Kuwait CLAP)登记处。2020年2月至2021年2月期间,被诊断为STEMI的成年患者(≥18岁)被纳入科威特CLAP登记处。患者被分为参保和未参保两类。共同主要结局是参保与未参保STEMI患者的住院死亡率和30天死亡率。还比较了住院期间和30天的不良心脏结局。
在668例STEMI患者中,116例(17%)参保,552例(83%)未参保。3例(2.6%)参保患者和9例(1.6%)未参保患者在住院期间死亡,而参保组无患者死亡,未参保组有4例患者(0.7%)在30天内死亡,两组之间无显著差异(分别为 = 0.447和 = 1)。两组的住院并发症发生率和30天不良事件发生率相似。
我们的研究结果表明,科威特不同保险状况的患者在急性或短期治疗结果方面没有差异。这些发现令人放心,因为知道科威特政府为STEMI患者提供的免费基本服务与参保患者相比,并未影响未参保患者的治疗结果。